08:09 AM EDT, 03/14/2024 (MT Newswires) -- Autolus Therapeutics ( AUTL ) reported a full-year 2023 net loss Thursday of $1.20 per share, narrowing from a loss of $1.57 a year earlier.

Analysts polled by Capital IQ expected a per-share loss of $1.10.

License revenue for the year ended Dec. 31 was $1.7 million, down from $6.2 million a year earlier.

Analysts surveyed by Capital IQ expected $1.7 million.

Price: 5.5, Change: +0.02, Percent Change: +0.36